Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: Systematic review and meta-analysis

Li, You-Wei; Chen, Zhengguang; Wang, Jichen; Zhang, Zongming

doi:10.3748/wjg.v21.i14.4334

Cited by 27 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SPIO/USPIO-enhanced MRI can improve the differentiation of HCC and other focal hepatic lesions. 41 , 42 , 43 Tailored SPIO/USPIO nanoparticles can also specifically target tumor cells through their coupling with aptamers, peptides and antibodies. 44 , 45 , 46 , 47 Recently, a bi-specific USPIO imaging probe was developed for HCC diagnosis by simultaneously conjugating AFP and GPC3 antibodies.…”

Section: Imagingmentioning

confidence: 99%

Advances in the early diagnosis of hepatocellular carcinoma

Wang¹,

Wei²

2020

Genes & Diseases

286

161

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers globally. In contrast to the declining death rates observed for all other common cancers such as breast, lung, and prostate cancers, the death rates for HCC continue to increase by ~2–3% per year because HCC is frequently diagnosed late and there is no curative therapy for an advanced HCC. The early diagnosis of HCC is truly a big challenge. Over the past years, the early diagnosis of HCC has relied on surveillance with ultrasonography (US) and serological assessments of alpha-fetoprotein (AFP). However, the specificity and sensitivity of US/AFP is not satisfactory enough to detect early onset HCC. Recent technological advancements offer hope for early HCC diagnosis. Herein, we review the progress made in HCC diagnostics, with a focus on emerging imaging techniques and biomarkers for early disease diagnosis.

show abstract

Section: Imagingmentioning

confidence: 99%

Advances in the early diagnosis of hepatocellular carcinoma

Wang¹,

Wei²

2020

Genes & Diseases

286

161

View full text Add to dashboard Cite

show abstract

“…Fe 3 O 4 is a type of ferromagnetic material, while the nano-spheres based on Fe 3 O 4 have a wide range of applications in biomedical and bioengineering elds due to their special physical, chemical, and biological properties [30]. Therapeutic drugs based on Fe 3 O 4 nanoparticles are gradually attracting increasing attention in medical areas due to its integration of both imaging and therapeutic functions into a single nanoagent, enabling accurate cancer diagnosis and personalized medical treatment as well as real-time monitoring of drug distribution and evaluation of treatment outcomes [31,32]. In recent years, with the rapid development of nanotechnology, the diagnosis and treatment of multifunctional and multimodal nanocarriers in the eld of biomedical applications have shown a signi cant potential.…”

Section: Discussionmentioning

confidence: 99%

Multifunctional PD-L1 Targeted Fe3O4@DOX Nanoparticles Under MRI Monitoring For Combination Therapy of Triple-Negative Breast Cancer

Zhao

Duan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The triple negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat, with currently restricted treatment of chemotherapy. However, evidence suggests that immunomotropy is only effective for a small portion of patients. The combination therapy of both immunotherapy and chemotherapy has demonstrated great promise in its treatment efficiency. However, this combination therapy is limited by both the organ toxicity of the chemotherapeutic drugs and the inaccessibility of the in vivo monitoring of individual tumor response to therapies. With the development of the nanomedicine, synchronous targeting therapy, imaging diagnosis and monitoring can be achieved convenientlly using the multifunctional nano-platform for TNBC. Results: In our study, we prepared the DOX loaded Fe3O4 nanoparticles targeting the PD-L1 (PD-L1@Fe3O4-DOX, FPD) to obtain the real-time magnetic resonance imaging (MRI) monitoring and combination therapy of both chemotherapy and immunotherapy for TNBC. The results showed that FPD inhibited tumor growth more effectively than either DOX chemotherapy or PD-L1 immunotherapy alone. Conclusion: Our study demonstrated that FPD has shown a great potential for theranostics and clinical translation in synchronous MRI imaging-guided monitoring and combined treatment of both DOX and immunotherapy of TNBC.

show abstract

“…in the case of pancreas transplantation during the treatment of diabetes mellitus, 50 whereas superparamagnetic nanoparticles characterised by iron oxide domains with sizes between 4-20 nm such as SiliFe have been suggested for MRI diagnostics of liver carcinoma. 51 Thus, both types are in general suited for the envisaged application.…”

Section: Discussionmentioning

confidence: 99%

Risk and life cycle assessment of nanoparticles for medical applications prepared using safe- and benign-by-design gas-phase syntheses

et al. 2020

View full text Add to dashboard Cite

show abstract

Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: Systematic review and meta-analysis

Abstract: SPIO-enhanced MRI is useful in differentiating between HCCs and other FHLs.

Cited by 27 publications

References 21 publications

Advances in the early diagnosis of hepatocellular carcinoma

Advances in the early diagnosis of hepatocellular carcinoma

Multifunctional PD-L1 Targeted Fe3O4@DOX Nanoparticles Under MRI Monitoring For Combination Therapy of Triple-Negative Breast Cancer

Risk and life cycle assessment of nanoparticles for medical applications prepared using safe- and benign-by-design gas-phase syntheses

Contact Info

Product

Resources

About